share_log

Biotricity Analyst Ratings

Benzinga Analyst Ratings ·  Feb 15, 2023 06:09
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
02/15/2023 184.33% HC Wainwright & Co. → $2 Reiterates → Buy
07/15/2022 Maxim Group Downgrades Buy → Hold
07/15/2022 184.33% HC Wainwright & Co. $6 → $2 Maintains Buy
03/07/2022 610.83% Lake Street → $5 Initiates Coverage On → Buy
11/23/2021 753% HC Wainwright & Co. → $6 Initiates Coverage On → Buy
07/01/2021 895.17% Northland Capital Markets → $7 Initiates Coverage On → Outperform

What is the target price for Biotricity (BTCY)?

The latest price target for Biotricity (NASDAQ: BTCY) was reported by HC Wainwright & Co. on February 15, 2023. The analyst firm set a price target for $2.00 expecting BTCY to rise to within 12 months (a possible 184.33% upside). 4 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Biotricity (BTCY)?

The latest analyst rating for Biotricity (NASDAQ: BTCY) was provided by HC Wainwright & Co., and Biotricity reiterated their buy rating.

When is the next analyst rating going to be posted or updated for Biotricity (BTCY)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biotricity, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biotricity was filed on February 15, 2023 so you should expect the next rating to be made available sometime around February 15, 2024.

Is the Analyst Rating Biotricity (BTCY) correct?

While ratings are subjective and will change, the latest Biotricity (BTCY) rating was a reiterated with a price target of $0.00 to $2.00. The current price Biotricity (BTCY) is trading at is $0.70, which is within the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment